Xuemei Liao

Title: Xuemei Liao: Innovator in Cancer Treatment

Introduction

Xuemei Liao is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. With a total of two patents to his name, Liao's work is paving the way for innovative therapies.

Latest Patents

Liao's latest patents include "Substituted pyrimidines as cyclin-dependent kinase inhibitors." This invention discloses a substituted pyridine compound represented by formula I, along with its pharmaceutically acceptable salts, stereoisomers, and tautomers. The compounds are particularly useful in treating various cancers. Another patent, also titled "Substituted pyrimidines as cyclin-dependent kinase inhibitors," reveals a nitrogen-containing fused heterocyclic compound. This compound exhibits high selectivity and inhibitory activity against CDK4 and CDK6 at a molecular level. It shows excellent inhibitory activity against breast cancer cells and significantly inhibits tumor cell proliferation associated with cyclin-dependent kinase activity at an animal level. The invention demonstrates good stability concerning human or mouse liver microsomes and shows high bioavailability and good druggability.

Career Highlights

Xuemei Liao is currently associated with Shanghai Pharmaceuticals Holding Co., Ltd. His work in this company has been instrumental in advancing cancer treatment options through innovative drug development.

Collaborations

Liao has collaborated with notable coworkers, including Guangxin Xia and Qian Wang, who contribute to his research efforts in the pharmaceutical field.

Conclusion

Xuemei Liao's innovative work in developing cyclin-dependent kinase inhibitors showcases his commitment to advancing cancer treatment. His contributions are vital in the ongoing fight against cancer, and his patents reflect the potential for significant medical breakthroughs.